A Nature Communications study examined whether GLP-1 receptor agonists affect tuberculosis risk in people with type 2 diabetes. The analysis, led by KM Liao, JY Wu, and CC Lai, sits at the intersection of two global health burdens—diabetes pharmacotherapy and infectious disease surveillance. The reported question is highly actionable for real-world prescribing and infection monitoring, because GLP-1 drugs are widely used and any association with TB risk would translate quickly into screening or risk-stratification strategies for vulnerable patients.